A.M. RAZUMOVSKAYA¹, M.I. RAZUMOVSKY², Y.A. KOROVIANSKY², E.S. RAZUMOVSKY³

¹Saint Petersburg Institute of Medical Experts Advanced Education, 11A Bolshoy Sampsonievsky Ave., Saint Petersburg, Russian Federation, 197101

 ²Federal Scientific Center for the Rehabilitation of the Disabled named after G.A. Albrekht, 50 Bestuzhevskaya Str., Saint Petersburg, Russian Federation, 195067

³ Saint Petersburg State Pediatric Medical University, 2 Litovskaya Str., Saint Petersburg, Russian Federation, 194100

  Razumovskaya A.M. — Cand. Med. Sc., Associate Professor, e-mail: amrazum@mail.ru

Razumovsky M.I. — D. Med. Sc., Professor, Honored Doctor of Russia, Head of the Department of Medical-social Expertise and Rehabilitation of the Blind and Visually Impaired, e-mail: razumir@mail.ru

Koroviansky Yu.A. — Cand. Med. Sc., ophthalmologist, e-mail: oft45320@gmail.com

Razumovsky E.S. — student, e-mail: zhenjarasum@gmail.com

 The aim of the research was to study the effectiveness of glaucoma neuroopticopathy treatment by the method of endonasal electrophoresis of Emoxypin and parabulbar injections of this medication.

Patients and methods:

A total of 106 patients with glaucoma neuroopticopathy participated in the study. Of these, 42 patients comprised the main group who received the researched medication by the method of endonasal electrophoresis: 0.5 ml of Emoxypin into each nasal duct; 64 patients formed the comparison group who received 0.5 ml of 1% Emoksipin solution through parabulbar injections.

In the gender aspect, there were 64 women and 42 men, aged 39 to 76 years (mean age 56.6 ± 8.2 years).

The studied medication Emoxypin — 1% solution for injections, in 1 ml ampoules,— was introduced by the method of endonasal electrophoresis into each nasal duct by 0.5 ml once a day. For comparison, the patients were examined who received 0.2-0.5 ml of 1% Emoxypin solution for injections once a day or every other day through parabulbar injections.

The ophthalmic examination included: study of visual acuity, field of vision, visual fatigue, state of bulbar microcirculation (general conjunctival index — OCI). In addition, electrophysiological studies were conducted: the critical flicker frequency (CFF) and the electric sensitivity of the eye (ES).

Data processing was carried out with Excel electronic database using the Statistica 7.0. and MedCalc software. The accepted threshold of statistical significance is 0.05.

Results:

In the course of the study it was proved that, for patients with glaucoma neuroopticopathy, Emoxypin 0.1% solution for injections is no less effective when administered with endonasal electrophoresis than through parabulbar injections and has a similar safety profile and tolerability.

Conclusion:

The estimation of effectiveness of Emoxypin administered by endonasal electrophoresis in glaucoma neuroopticopathy has shown its significant positive therapeutic effect for visual functions restoration.

None of the authors has a financial interest in the materials or methods presented. The authors declare that they have no conflict of interest.

Key words: glaucoma neuroopticopathy, Emoxypine, endonasal electrophoresis, parabulbar injections

 REFERENCES

1. Libman E.S., Shakhova E.V. Blindness and disability due to pathology of the organ of vision in Russia. Vestnik oftalʹmologii, 2006, no. 1, pp. 35–37 (in Russ.).
2. Libman E.S., Shakhova E.V., Chumaeva E.A., Elʹkina Ya.Eh. Invalidnostʹ vsledstvie glaukomy v Rossii [Disability due to glaucoma in Russia]. Glaukoma: problemy i resheniya: sb. nauch. st. Moscow, 2004. Pp. 430–432.
3. Glaukoma. Natsionalʹnoe rukovodstvo, pod. red E.A. Egorova [Glaucoma. National leadership. Under. ed. by E.A. Egorov]. Moscow: GEHOTAR-Media, 2013. 824 p.
4. Kurysheva N.I. Glaukomnaya opticheskaya neyropatiya [Glaucoma optic neuropathy]. Moscow: MEDpressinform, 2006. 136 p.
5. Flammer D. Glaukoma. World; Wide Printing, 2003. 345 p.
6. Flammer J., Mozaffarieh M. Modern pathogenetic concept of glaucoma optic neuropathy. Glaukoma. 2007, no. 4, pp. 3–15 (in Russ.).
7. Lei Y., Garrahan N., Hermann B. et al. Topography of neuron loss in the retinal ganglion cell layer in human glaucoma. Br. J. Ophthalmol, 2009, vol. 93, pp. 1676–1679.
8. Schumer R.A., Rodos S.M. The nerve of glaucoma. Arch. Ophthalm, 1994, no. 1, pp. 37–44.
9. Ferreras A. et al. Logistic Regression Analysis for Early Glaucoma Diagnosis Using Optical Coherence Tomography. Arch Ophthalmol., 2008, no. 126, pp. 465–470.
10. Nesterov A.P. Glaukoma. Moscow: Meditsinskoe informatsionnoe agentstvo, 2008. 360 p.
11. Razumovskiy M.I., Kolyuka O.E., Razumovskaya A.M. Assessment of labor opportunities for the visually impaired by complex electrophysiological and ophthalmoergonomic method. Oftalʹmologiya, vol. 11, no. 1, 2014, pp. 52–56 (in Russ.).
12. Razumovskiy M.I., Razumovskaya A.M. Assessment of visual possibilities in the work process of the visually impaired. Oftalʹmologiya, vol. 11, no. 1, 2014, pp. 58–61 (in Russ.).
13. Chaban T.N. Girudoterapiya v ambulatornoy oftalʹmologii [Hirudotherapy in outpatient ophthalmology]. Lechenie meditsinskimi piyavkami i preparatami iz nikh: sb. st. po mater, nauch.-prakt. konf. Lyubertsy, 2003. Book 2. Pp. 13–14.
14. Kim S.J., Kim Y.J., Park K.H. Neuroprotective effect of transpupillary thermotherapy in the optic nerve crush model of the rat. Eye, 2009, vol. 23, pp. 727–733.
15. Yoles E., Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv. Ophthalmol, 1998, vol. 42, no. 4, pp. 367–372.
16. Schachtsabel D.O., Binniger E. Stimulatory effects of ascorbic acid on hyaloronic acid synthesis of in vitro cultured normal and glaucomatous trabecular meshwork cells of the human eye. Z. Gerontol., 1993, no. 4, pp. 243–246.
17. Karushin O.I. Novye podkhody v lechenii glaukomatoznoy atrofii zritelʹnogo nerva [New approaches in the treatment of glaucomatous atrophy of the optic nerve]. X sʺezd oftalʹmologov Ukrainy: tez. dokl. Odessa, 2002. Pp. 186–187.
18. Kornilaeva M.P. Maloinvazivnaya khirurgiya atrofii zritelʹnogo nerva pri pervichnoy glaukome [Minimally invasive surgery of optic atrophy in primary glaucoma]. VIII sʺezd oftalʹmologov Rossii: tez. dokl. Moscow, 2005. P. 185.
19. Levin L.A. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy Text. Surv. Ophthalmol., 1999, vol. 43, no. 1, pp. 98–101.
20. Borisova N.A., Rakhimkulov A.S., Khaziakhmetov R.M., Rizvanova A.S., Avertsev G.N. Endonasal electrophoresis with ceruloplasmin, cerebrolyzate and tanakan in cerebrovascular diseases. Nizhegorodskiy meditsinskiy zhurnal, 2003; 2:111–114 (in Russ.).
21. Rakhimkulov A.S., Borisova N.A., Kachemaev V.P. Results of treatment of initial forms of cerebrovascular diseases using iodine-bromine baths and ceruloplasmin. Meditsinskiy Vestnik Bashkortostana. 2014;9(3):88–91 (in Russ.).
22. Ponomarenko G.N., Vorobʹev M.G. Rukovodstvo po fizioterapii [Manual for physiotherapy]. Saint Petersburg: IITS Baltika, 2005. 400 p.